Dataset

This dataset was created by Daniel Ansted

Released under CC0: Public Domain

Contents

This is synthetic patient-level clinical trial data, re-created based on data from a clinical trial for corticosteroids and antiviral agents as treatment for Bell's Palsy: https://www.nejm.org/doi/full/10.1056/nejmoa072006#

Bell's Palsy is a sudden, temporary weakness or paralysis of the muscles on one side of the face. The exact cause is unknown, but it's believed to occur due to swelling and inflammation of the nerve that controls the muscles on one side of the face, which can be triggered by a viral infection.

The authors conducted a double-blind, placebo-controlled, randomized, factorial trial involving patients with Bell's Palsy who were recruited within 72 hours after the onset of symptoms. Patients were randomly assigned to receive 10 days of treatment with prednisolone, acyclovir, both agents, or placebo. The primary outcome was recovery of facial function, as rated on the House–Brackmann scale.

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F4146319%2Ffcf4a8da1954977c5b94ca11caee6079%2Fhouse_brackmann_scale.jpg?generation=1693081683813509&alt=media" alt="">

This data package contains datasets on clinical trials conducted in the United States. Diseases include cervical cancer, diabetes, acute respiratory infection as well as stress. This data package also includes clinical trials registry and results database.

The Clinical Trials Registry and Results Database compiles information on publicly and privately supported clinical trial studies on a wide range of diseases and conditions. Its main goal is to provide an easy access to both privately and publicly funded clinical trials information for patients, their family members, healthcare professionals, researchers, and the public.

In 2023, 17 percent of all clinical drug trials worldwide were started in North America, whereas 29 percent of trials were initiated in China. This statistic shows the geographical distribution of clinical drug trials started worldwide from 2013 to 2023, by region.

This statistic shows the number of registered clinical studies worldwide by location, as of June 13, 2025. The number of registered clinical studies in non-U.S. areas was at around 303 thousand, while in the U.S. the number was at around 159 thousand.

Research dataset and analysis for Clinical Trials including statistics, forecasts, and market insights

The DIRECCT study is a multi-phase, living examination of clinical trial results dissemination throughout the COVID-19 pandemic. This dataset contains trials, registrations, and results from Phase 1 of the project, examining trials completed during the first six months of the pandemic (i.e., through 30 June 2020). This dataset is provided as a relational database of three CSVs which can joined on the id column. Data was collected using a combination of automated and manual strategies; automated searches were performed on 30 June 2020, and manual searches were performed between 21 October 2020 and 18 January 2021. Data sources for trials and registrations include the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) list of registered COVID-19 studies, individual clinical trial registries, and the COVID-19 TrialsTracker (https://covid19.trialstracker.net/). Data sources for results include COVID-19 Open Research Dataset Challenge (CORD-19), PubMed, EuropePMC, Google Scholar, and Google. Additional information on the project is available at the project's OSF page: http://doi.org/10.17605/osf.io/5f8j2

Snapshot img

Clinical Trial Management System Market Size 2024-2028

The clinical trial management system (CTMS) market size is valued to increase USD 1.86 billion, at a CAGR of 14.27% from 2023 to 2028. Increasing healthcare expenditure will drive the clinical trial management system (ctms) market.

Major Market Trends & Insights

North America dominated the market and accounted for a 42% growth during the forecast period.
By Deployment - On-premise segment was valued at USD 716.20 billion in 2022
By End-user - Pharmaceutical and biotechnology companies segment accounted for the largest market revenue share in 2022

Market Size & Forecast

Market Opportunities: USD 230.98 million
Market Future Opportunities: USD 1861.00 million
CAGR : 14.27%
North America: Largest market in 2022

Market Summary

The market represents a dynamic and evolving sector in the healthcare industry. With increasing healthcare expenditure worldwide, the outsourcing of clinical trial processes has become a preferred strategy for pharmaceutical and biotech companies to reduce costs and improve efficiency. According to a recent report, the global CTMS market is expected to witness significant growth, with a notable increase in adoption rates. Core technologies such as electronic data capture (EDC) and randomization and trial supply management (RTSM) are driving this growth, enabling real-time data access and streamlined trial processes. However, challenges persist, including regulatory compliance and data security concerns. In Europe, for instance, the implementation of the EU Clinical Trials Regulation (CTR) has led to increased scrutiny and stricter requirements for CTMS solutions.
Despite these challenges, opportunities abound, particularly in emerging markets and in the integration of CTMS with other healthcare technologies, such as electronic health records (EHRs) and artificial intelligence (AI). The CTMS market is poised for continued innovation and growth, offering significant potential for stakeholders in the healthcare ecosystem.

What will be the Size of the Clinical Trial Management System (Ctms) Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free Sample

How is the Clinical Trial Management System (Ctms) Market Segmented and what are the key trends of market segmentation?

The clinical trial management system (ctms) industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Deployment

  On-premise
  Cloud


End-user

  Pharmaceutical and biotechnology companies
  CROs
  Others


Component

  Software
  Services


Product Type

  Enterprise CTMS
  Site CTMS


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  Middle East and Africa

    Egypt
    KSA
    Oman
    UAE


  APAC

    China
    India
    Japan


  South America

    Argentina
    Brazil


  Rest of World (ROW)

By Deployment Insights

The on-premise segment is estimated to witness significant growth during the forecast period.

In the dynamic and evolving clinical trials landscape, the market plays a pivotal role in ensuring data integrity, subject tracking, and regulatory compliance. According to recent reports, the market for CTMS solutions is currently experiencing significant growth, with adoption increasing by 18.7% in the past year. Furthermore, industry experts anticipate that this trend will continue, with market expansion projected to reach 21.6% in the coming years. Key components of CTMS include electronic data capture (EDC) systems, case report forms (CRFs), electronic clinical record forms (eCRFs), and safety reporting systems. These tools facilitate efficient data management, streamline workflows, and enhance regulatory compliance.

Integrated systems that combine these features with randomization tools, investigator portals, and data visualization capabilities further augment their value. Moreover, the importance of data privacy regulations, such as the Health Insurance Portability and Accountability Act (HIPAA) and the European Union's General Data Protection Regulation (GDPR), has led to the development of advanced security measures. These include data validation rules, data cleaning processes, and audit trails. Despite the benefits of CTMS, challenges persist. Large firms, particularly those with extensive resources, continue to prefer on-premises solutions for their perceived data security advantages. However, the high costs of infrastructure investment and maintenance have prompted many organizations to explore alternative options.

In the future, the market is expected to witness continued innovation, with developments in areas such as centralized data storage, risk-b

The Decentralized Clinical Trials Market Report is Segmented by Study Design (Interventional, and More), Component (Cloud-Based Platforms, and More), Therapeutic Application (Oncology, Cardiology, and More), End-User (Pharmaceutical & Biotech Sponsors, and More), Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

In the period from 2018 to 2023, 28 percent of clinical drug trials started during these years were in the field of oncology, whereas a combined 13 percent of trials started were for infectious diseases (therapeutic and immunization). This statistic depicts the proportion of clinical trials started worldwide from 2018 to 2023, by key therapeutic area.

The clinical trials market size was USD 92.7 billion in 2025 and is expected to reach USD 169 billion by the end of 2035, increasing at a CAGR of 6.9% during the forecast period, i.e., 2026-2035. North America industry is predicted to account for the largest share of 44.6% by 2035, owing to an increase in the regional patient pool and continuous upliftment in oncology clinical trials in the region.

A listing of data sets from NIMH-supported clinical trials. Limited Access Datasets are available from numerous NIMH studies. NIMH requires all investigators seeking access to data from NIMH-supported trials held by NIMH to execute and submit as their request the appropriate Data Use Certification pertaining to the trial. The datasets distributed by NIMH are referred to as limited access datasets because access is limited to qualified researchers who complete Data Use Certifications.

Virtual clinical trials market size is estimated to grow from USD 12.4 bn in 2024 to USD 12.9 bn in 2025 and USD 30.5 bn by 2035, representing a CAGR of 9.0%

Clinical trials of drugs mentioning AI have grown leaps and bounds since 2016, growing by around ***** percent year-on-year, a staggering jump. This has some ethical considerations as AI is not yet fully tested as a technology and the degree to which AI is included in each trial will have a significant impact on its validity.

Snapshot img

Clinical Trial Supplies Market Size 2024-2028

The clinical trial supplies market size is valued to increase USD 1.31 billion, at a CAGR of 8.65% from 2023 to 2028. Growth of biopharmaceutical industry will drive the clinical trial supplies market.

Major Market Trends & Insights

North America dominated the market and accounted for a 37% growth during the forecast period.
By End-user - Pharmaceutical industry segment was valued at USD 907.30 billion in 2022
By Type - Phase III segment accounted for the largest market revenue share in 2022

Market Size & Forecast

Market Opportunities: USD 109.77 million
Market Future Opportunities: USD 1312.90 million
CAGR : 8.65%
North America: Largest market in 2022

Market Summary

The market encompasses a dynamic and continually evolving landscape, driven by the expanding biopharmaceutical industry and increasing demand for Contract Research Organizations (CROs) to manage clinical trials. With the global biopharmaceutical market projected to reach a value of USD765.6 billion by 2025, the need for reliable clinical trial supplies has become increasingly crucial. However, the high cost of clinical trials remains a significant challenge, with some estimating the average cost of bringing a new drug to market reaching USD2.6 billion.
Despite this, the market continues to grow, fueled by advancements in core technologies such as electronic data capture and remote monitoring systems, which streamline trial processes and improve data accuracy. Additionally, stringent regulations, including those set by the FDA and EMA, ensure the highest standards of safety and efficacy for clinical trial participants.

What will be the Size of the Clinical Trial Supplies Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free Sample

How is the Clinical Trial Supplies Market Segmented and what are the key trends of market segmentation?

The clinical trial supplies industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

End-user

  Pharmaceutical industry
  Biologics industry
  Medical device industry


Type

  Phase III
  Phase II
  Phase IV and BE/BA studies
  Phase I


Service

  Manufacturing
  Packaging and Labeling
  Storage and Distribution
  Comparator Sourcing
  Ancillary Supplies
  Others


Therapeutic Area

  Oncology
  Cardiovascular Diseases
  Neurology
  Infectious Diseases
  Metabolic Disorders
  Others


Distribution Channel

  Direct-to-Site
  Depot-to-Site
  Others


Geography

  North America

    US


  Europe

    Germany
    UK


  APAC

    China
    Japan


  Rest of World (ROW)

By End-user Insights

The pharmaceutical industry segment is estimated to witness significant growth during the forecast period.

The market is a significant segment within the life sciences industry, primarily driven by the pharmaceutical sector. With the continuous development of new drugs and the increasing prevalence of chronic and epidemic diseases, the demand for clinical trials is on the rise. According to recent reports, the pharmaceutical industry holds the largest market share in clinical trial supplies, accounting for approximately 60% of the total market. Clinical trials are a crucial step in the drug development process, ensuring the safety, efficacy, and performance of new drugs before they reach the market. The regulatory landscape, particularly the FDA, plays a pivotal role in this process by enforcing stringent guidelines to ensure the safety and efficacy of new drugs and personalized medicine.

As a result, the demand for clinical trial materials, such as biospecimen management, clinical trial documentation, data management systems, patient recruitment, packaging materials, adverse event reporting, storage and handling, drug product labeling, supply chain traceability, and medical device supplies, is growing. Furthermore, the market is expected to expand at a steady pace, with forecasts indicating a potential increase of around 15% in the next three years. This growth can be attributed to the continuous development of new drugs, the increasing prevalence of chronic and epidemic diseases, and the growing trend towards personalized medicine. Additionally, advancements in technology, such as temperature-controlled shipping, inventory tracking systems, and real-time tracking, are revolutionizing the market, making it more efficient and effective.

Moreover, the market is witnessing significant developments in various sectors, including pharmaceutical logistics, protocol adherence, kitting and assembly, warehouse management, and order fulfillment. For instance, the use of investigational medicinal products in clinical trials is increasing, drivin

According to Cognitive Market Research, the global Virtual Clinical Trials market size will be USD 9860 million in 2025. It will expand at a compound annual growth rate (CAGR) of 6.20% from 2025 to 2033.

North America held the major market share for more than 40% of the global revenue with a market size of USD 3648.20 million in 2025 and will grow at a compound annual growth rate (CAGR) of 4.7% from 2025 to 2033.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 2859.40 million.
APAC held a market share of around 23% of the global revenue with a market size of USD 2366.40 million in 2025 and will grow at a compound annual growth rate (CAGR) of 8.9% from 2025 to 2033.
South America has a market share of more than 5% of the global revenue with a market size of USD 374.68 million in 2025 and will grow at a compound annual growth rate (CAGR) of 6.9% from 2025 to 2033.
Middle East had a market share of around 2% of the global revenue and was estimated at a market size of USD 394.40 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.5% from 2025 to 2033.
Africa had a market share of around 1% of the global revenue and was estimated at a market size of USD 216.92 million in 2025 and will grow at a compound annual growth rate (CAGR) of 6.5% from 2025 to 2033.
Interventional category is the fastest growing segment of the Virtual Clinical Trials industry

Market Dynamics of Virtual Clinical Trials Market

Key Drivers for Virtual Clinical Trials Market

Technology's Expanding Application in Healthcare to Boost Market Growth

The current approach to conducting a traditional clinical trial is coming to an end because of the expensive mix of growing trial expenses and the potential for commercial failure. As we get closer to a more digitalised environment, the use of advanced technology is increasingly driving clinical investigations and rapidly accelerating the digital transformation of their operations. Clinical studies are necessary. Thus a solution to the problems with traditional clinical trials is to move to cutting-edge technology and digital innovation. Once only concepts, digital clinical trials are now on the verge of becoming a reality. Digital technologies are transforming the entire process of developing new drugs. Artificial intelligence, cloud computing, wearable and mobile technology, and associated platforms have all advanced, making it feasible to gather frequent, accurate, and multidimensional data throughout trials. For instance, in August 2022, a new software program introduced by Medable Inc. helped to streamline virtual/decentralized clinical trials for vaccinations. This program was expected to reduce deployment time by 50% and provide access to clinical trials worldwide.

https://www.medable.com/newsroom/medable-simplifies-decentralized-clinical-trials-for-vaccines-expands-global-trial-access-while-cutting-deployment-time-by-50-51

Supportive Government Initiatives To Boost Market Growth

The FDA has taken an open approach to new ideas and developments in technology. According to the FDA, there are benefits to appropriately utilising the technology in clinical research. One of the earliest papers on electronic informed consent for medical research was this one. A number of non-regulatory initiatives, with the assistance of regulators, are developing guidelines for the use of virtual tools in trial design. For example, standards for virtual clinical trials using telemedicine and mobile healthcare providers have been established by the FDA-sponsored Clinical Trial Transformation Initiative. By understanding the confluence of people, information, technology, and connections to improve healthcare and health outcomes, the FDA is more progressive than sponsors and drug development organisations with conservative views.

Restraint Factor for the Virtual Clinical Trials Market

Regulatory Hurdles Will Limit Market Growth

The stringent laws and regulations are one of the main things that are anticipated to impede the expansion of the worldwide market for virtual clinical trials. The Food and Drug Administration (FDA), for example, regulates clinical trials in the United States to make sure they are planned, carried out, evaluated, and reported in compliance with federal law and good clinical practice guidelines. However, maintaining IT infrastructure for clinical trial coordination and advanci...

Clinical Trial Data Repository Market Outlook

The global clinical trial data repository market size was estimated to be approximately $1.8 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 9.5% to reach around $4.1 billion by 2032. The primary growth factors include the increasing volume and complexity of clinical trials, rising need for efficient data management systems, and stringent regulatory requirements for data accuracy and integrity. The advent of advanced technologies such as artificial intelligence and big data analytics further drives market expansion by enhancing data processing capabilities and providing actionable insights.

The growth of the clinical trial data repository market is significantly influenced by the increasing number of clinical trials being conducted globally. With the rise in chronic diseases, the need for innovative treatments and therapies has surged, leading to an upsurge in clinical trials. This increase in clinical trials necessitates robust data management systems to handle vast amounts of data generated, thereby propelling the demand for clinical trial data repositories. Moreover, the complexity of modern clinical trials, which often involve multiple sites and diverse patient populations, further amplifies the need for sophisticated data management solutions.

Another critical driver for the market is the stringent regulatory landscape governing clinical trial data. Regulatory bodies such as the FDA, EMA, and other local authorities mandate rigorous data management standards to ensure data integrity, accuracy, and accessibility. These regulations necessitate the adoption of advanced data repository systems that can comply with regulatory requirements, thereby fueling market growth. Additionally, regulatory frameworks are becoming increasingly stringent, prompting pharmaceutical and biotechnology companies to invest in state-of-the-art data management systems to avoid compliance issues and potential financial penalties.

Technological advancements play a pivotal role in the market's growth. The integration of artificial intelligence, machine learning, and big data analytics into data repository systems enhances data processing and analysis capabilities. These technologies enable real-time data monitoring, predictive analytics, and improved decision-making, thereby improving the efficiency of clinical trials. Furthermore, the shift towards cloud-based solutions offers scalability, flexibility, and cost-effectiveness, making advanced data management systems accessible to even small and medium-sized enterprises.

Regionally, North America dominates the clinical trial data repository market owing to its robust healthcare infrastructure, high R&D investments, and presence of major pharmaceutical and biotechnology companies. Europe follows closely due to stringent regulatory standards and a strong focus on clinical research. The Asia Pacific region is expected to witness the highest growth rate during the forecast period due to increasing clinical trial activities, growing healthcare expenditure, and the rising adoption of advanced technologies. Latin America and the Middle East & Africa are also likely to experience growth, albeit at a slower pace, driven by improving healthcare systems and increasing focus on clinical research.

Component Analysis

The clinical trial data repository market is segmented by components into software and services. The software segment is anticipated to hold a significant share of the market due to the essential role software plays in data management. Advanced software solutions offer capabilities such as data storage, management, retrieval, and analysis, which are critical for effective clinical trial management. The integration of AI and machine learning algorithms into these software systems further enhances their efficiency by enabling predictive analytics and real-time monitoring, thus driving the software segment's growth.

Software solutions in clinical trial data repositories also offer interoperability, enabling seamless integration with other clinical trial management systems (CTMS) and electronic data capture (EDC) systems. This interoperability is crucial for ensuring data consistency and accuracy across different platforms, thereby enhancing overall data management. Additionally, the increasing adoption of cloud-based software solutions provides scalability, cost-effectiveness, and remote acce

The Clinical Trial Platform market is booming, projected to reach $2.255 Billion by 2033 with a 6.8% CAGR. This comprehensive analysis explores market drivers, trends, and leading companies like Medable, Veeva, and Oracle Health Sciences, offering insights for investors and stakeholders in the pharmaceutical and healthcare sectors. Learn more about decentralized clinical trials (DCTs) and the future of clinical research.

A total of 203 clinical trials started in Denmark during the year 2023. The number of clinical trials peaked in 2021, exceeding 300 trial starts.